Our business is built on our inherent strengths – KKCG's size and resources, ability to succeed in new markets, expertise in the IT and biotechnology sectors, and experience with effective management.
1/3 our success
emlpoyees
in revenues in 2018
The ARICOMA Group's establishment marks the completion of the many years during which KKCG focused on the high-potential sector of information technologies. The IT sector currently offers excellent investment opportunities, mainly thanks to the globally growing complexity of ICT solutions and the consequent rise in demand for ICT services.
2/3 our success
in Geewa sold to American tech company AppLovin, based in Palo Alto, California
in SPOT purchased by NetApp
The Springtide Venture fund, part of the KKCG Group, has sold stakes in the Geewa development studio and the SPOT start-up to major American tech companies. Both of these commercial transactions confirm the correctness of the initial investments, and demonstrated the potential in new technologies.
3/3 our success
was Conectart part of the KKCG Group
where Conectart call centres are
working in the field of Business Process Outsourcing
Summer 2020 saw the completion of a commercial transaction that resulted in the successful sale of Conectart to the Genesis Capital group.
With a portfolio comprising leading Czech and foreign companies, ARICOMA's strategy is based on the trend that more and more businesses are changing the ways in which they use IT services. The goal is to provide new-generation IT services that guarantee comprehensive coverage for customers' diverse needs. Our flagship, AUTOCONT, specializes in ICT corporate infrastructure and enterprise information systems. We develop software and provide IT outsourcing, ICT security, and cloud services, and our portfolio includes contact centers. We have state-of-the-art data centers in Prague and South Moravia that offer not only secure storage, but also maximum data exploitability. The reliability of our data centers is guaranteed by Tier III certification.
We rely on partnerships with global technology leaders and the extensive expertise of our professionals. Our vision is to create permanent value based on strong and lasting partnerships with the entrepreneurs we support, and with other investors. We are a partner to small and large enterprises in helping them streamline IT operations, reduce operating costs, and improve flexibility to facilitate the implementation of development plans.
Biotechnology research and the transfer of the results derived from it to the marketplace is a very costly, high-risk enterprise. KKCG is one of a small number of Czech corporations engaged in this area. We develop state-of-the-art medical devices that improve the quality of life for patients. We make unique cervical dilators and oversee the development of new products, mainly innovative solutions for tissue regeneration and augmentation and eye surgery. Our funding provides support for clinical trials of MitoTam, a cancer drug developed by Professor Jiří Neužil at the Institute of Biotechnology.
